Regeneron Seeks MDL Docket for Eylea Patent Infringement Cases



DOCUMENTS
  • Motion


WASHINGTON, D.C. — The JPML has been asked to create an MDL docket for lawsuits in which Regeneron Pharmaceuticals Inc. accuses other drug makers, including Amgen Inc., of violating its patent rights by seeking approval of biosimilars of its blockbuster eye drug Eylea (aflibercept).

In a Jan. 11 motion, Regeneron has asked the panel to transfer Regeneron Pharmaceuticals, Inc. v. Amgen Inc., pending in the U.S. District Court for the Central District of California, to Chief Judge Thomas S. Kleeh of the Northern District of West Virginia for coordinated pretrial proceedings with five cases already pending in that district.

In …






UPCOMING CONFERENCES




HarrisMartin's New Jersey Asbestos Litigation Conference

March 01, 2024 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS



HarrisMartin's Ozempic MDL Conference: Updates from the Status Hearing

March 15, 2024 - Philadelphia, PA
Kimpton Hotel Monaco Philadelphia

MORE DETAILS